
In a phase 3 study of previously treated patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer, crizotinib (Xalkori, Pfizer) more than doubled median progression free survival than when treated with standard chemotherapy, according to a study published June 1, 2013 online in New England Journal of Medicine.